Thrombectomy Device
Viper Catheter System for Pulmonary Embolism
This trial is testing the safety and feasibility of a new device called the Viper Catheter System, which is designed to remove blood clots from the lungs of patients with serious but not fully blocking clots. The device works by being inserted into the blood vessels and physically extracting the clots to help restore normal blood flow.
Popular Filters
Trials for PE Patients
Thrombolytic Agent
Catheter-directed Thrombolysis for Pulmonary Embolism
This trial compares two treatments for blood clots in the lungs in patients at higher risk of complications. One treatment uses only blood thinners, while the other combines blood thinners with a device that uses sound waves to break up clots. The goal is to see which treatment is better at reducing serious problems and death.
Thrombolytic Agent
Reduced-Dose Thrombolytic Therapy for Pulmonary Embolism
This trial tests a smaller dose of a clot-busting drug combined with a blood thinner in patients with serious lung clots. The goal is to see if this approach is effective and safer than higher doses, reducing the risk of severe bleeding.
Anticoagulant
Low-Intensity Apixaban for Blood Clots
This trial is testing low-intensity apixaban versus placebo for extended prevention of recurrence after provoked VTE in patients with at least one persistent provoking factor. The primary safety outcome is ISTH major bleeding at 12 months, and the primary efficacy outcome is symptomatic, recurrent VTE at 12 months.
PET Probe
64Cu-FBP8 PET-CT Imaging for Blood Clots
This trial is testing a new imaging tool that helps doctors see fresh blood clots in patients with PE and DVT. It uses a special substance that binds to the clots, making them visible on a PET scan. This could improve diagnosis, especially for patients with kidney or lung problems.
Trials for Deep Vein Thrombosis Patients
Anticoagulant
Low-Intensity Apixaban for Blood Clots
This trial is testing low-intensity apixaban versus placebo for extended prevention of recurrence after provoked VTE in patients with at least one persistent provoking factor. The primary safety outcome is ISTH major bleeding at 12 months, and the primary efficacy outcome is symptomatic, recurrent VTE at 12 months.
PET Probe
64Cu-FBP8 PET-CT Imaging for Blood Clots
This trial is testing a new imaging tool that helps doctors see fresh blood clots in patients with PE and DVT. It uses a special substance that binds to the clots, making them visible on a PET scan. This could improve diagnosis, especially for patients with kidney or lung problems.
Phase 3 Trials
Thrombolytic Agent
Reduced-Dose Thrombolytic Therapy for Pulmonary Embolism
This trial tests a smaller dose of a clot-busting drug combined with a blood thinner in patients with serious lung clots. The goal is to see if this approach is effective and safer than higher doses, reducing the risk of severe bleeding.
Monoclonal Antibodies
Abelacimab vs Dalteparin for Blood Clot Prevention in Cancer Patients
This trial compares a new medication, Abelacimab, to another treatment, Dalteparin, in patients with GI or GU cancer who have had blood clots. The goal is to see which treatment better prevents new clots and reduces bleeding risks.
Monoclonal Antibodies
Abelacimab vs Apixaban for Cancer-Related Blood Clots
This trial is testing abelacimab, a medication, to prevent blood clots in cancer patients who have had previous clots. It aims to see if it works better and causes fewer bleeding problems compared to a current treatment.
Trials With No Placebo
Thrombolytic Agent
Catheter-directed Thrombolysis for Pulmonary Embolism
This trial compares two treatments for blood clots in the lungs in patients at higher risk of complications. One treatment uses only blood thinners, while the other combines blood thinners with a device that uses sound waves to break up clots. The goal is to see which treatment is better at reducing serious problems and death.
PET Probe
64Cu-FBP8 PET-CT Imaging for Blood Clots
This trial is testing a new imaging tool that helps doctors see fresh blood clots in patients with PE and DVT. It uses a special substance that binds to the clots, making them visible on a PET scan. This could improve diagnosis, especially for patients with kidney or lung problems.
View More Related Trials
Frequently Asked Questions
Introduction to pulmonary embolism
What are the top hospitals conducting pulmonary embolism research?
When it comes to advancing the understanding and treatment of pulmonary embolism, several top hospitals are leading the way in clinical trials. Brigham and Women's Hospital in Boston has emerged as a frontrunner with four ongoing trials dedicated to this condition. With a total of 24 previous trials under their belt, dating back to their first recorded trial in 2005, this hospital is at the forefront of breakthrough research. Duke University Medical Center in Durham also stands out with three active pulmonary embolism trials and eight completed studies since their pioneering trial in 2008.
In addition, Massachusetts General Hospital, another prominent institution based in Boston, is actively engaged in three current clinical trials for pulmonary embolism while having conducted 17 previous investigations since their inaugural study on this condition back in 2005. Across the Atlantic Ocean resides London Health Sciences Centre located within London - an exceptional hospital that is making significant strides toward understanding pulmonary embolism. They currently have three active clinical trials underway with six historical studies undertaken since recording their first groundbreaking trial all the way back to1998.
Lastly but certainly not least University of Pennsylvania situated within Philadelphia has contributed significantly towards advancing knowledge about pulmonary embolism by initiating its own set of meticulously structured exploratory undertakings starting from as recently as2016 resulting into formulation & implementation of around four such successful endeavors till now
These esteemed institutions are committed not only to treating patients suffering from this potentially life-threatening condition but also dedicated to expanding our knowledge through innovative research methodologies. Through collaborative efforts and cutting-edge discoveries made at these hospitals worldwide progress continues towards unlocking new treatments and strategies ensuring better outcomes for those affected by pulmonary embolism
Which are the best cities for pulmonary embolism clinical trials?
When it comes to pulmonary embolism clinical trials, several cities emerge as key centers for research. Boston, Massachusetts leads the way with 12 active trials focusing on treatments such as Enteric Coated Aspirin, Investigational Device, and Anticoagulation using the EkoSonicTM Endovascular System. New york, New York follows closely behind with 10 ongoing studies investigating Anticoagulation therapies alongside the EkoSonicTM Endovascular System and AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 PE. Additionally, Philadelphia, Pennsylvania contributes significantly to this field with 9 active trials exploring treatments like Abelacimab and Non-Randomized Absolute Contraindication to Thrombolytics Cohort. Each of these cities plays a crucial role in advancing our understanding of pulmonary embolism and developing innovative approaches that can improve patient outcomes.
Which are the top treatments for pulmonary embolism being explored in clinical trials?
Exciting advancements are happening in the world of pulmonary embolism treatment, with clinical trials exploring various promising options. One notable contender is abelacimab, currently being tested in two active trials specifically targeting pulmonary embolism. Despite its recent entry into the scene in 2022, it has quickly gained attention for its potential effectiveness. Another noteworthy treatment under investigation is alteplase, which has one ongoing trial dedicated to studying its impact on pulmonary embolism. Having made its debut in 2016 and accumulating a total of six all-time trials related to this condition, alteplase shows promise as a potential therapeutic option. With each trial contributing valuable insights, researchers strive to enhance the arsenal against pulmonary embolism and improve patient outcomes.
What are the most recent clinical trials for pulmonary embolism?
Recent clinical trials for pulmonary embolism offer promising advancements in treatment options. One notable study is investigating the effectiveness of transfusion and phlebotomy patients, specifically in Phase 2. Additionally, another trial explores catheter-directed therapy (CDT) combined with anticoagulation as a potential approach for managing pulmonary embolism during Phase 3. Low dose TS23 also shows promise as a treatment option for this condition in its ongoing Phase 2 trial. With these innovative studies paving the way forward, individuals affected by pulmonary embolism can anticipate improved outcomes and enhanced care soon.
What pulmonary embolism clinical trials were recently completed?
Recently completed clinical trials have made significant strides in the field of pulmonary embolism, offering potential advancements in treatment for this serious condition. In January 2019, Northwell Health concluded a trial investigating the efficacy of Alteplase. Likewise, Brigham and Women's Hospital completed a trial in September 2018 to evaluate Ferumoxytol as a possible therapeutic option. Additionally, Daiichi Sankyo, Inc.'s Edoxaban study wrapped up in March 2017. These research endeavors highlight ongoing efforts to enhance our understanding and management of pulmonary embolism for the benefit of patients worldwide.